about
Driving delivery vehicles with ultrasound.Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapiesDetection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.Investigational antibody drug conjugates for solid tumors.Latent cytokines for targeted therapy of inflammatory disorders.Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth.Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis.Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritisChronic cardiac allograft rejection: critical role of ED-A+fibronectin and implications for targeted therapy strategies
P2860
Q30483826-7584FEC0-D7C4-4499-B923-AC006AFE7700Q34756337-D101885F-312B-4864-8CA1-74EFEF49F6B1Q37222913-AF032717-0EA2-4038-AF0E-C24207EAD0C5Q37258167-0AA62143-7DE0-4536-A960-FA28E801D683Q37330712-8E3A6F05-772A-4069-9071-63F9BA4B7E26Q37619943-1AF37A13-54F3-46B4-8972-FED36D7DC909Q37877745-E59D26AC-19C8-49AC-843D-CBA523141A33Q38167818-B454BC5B-C2EB-4B4D-96C5-3A7E6EBCF1FFQ38308741-A84CD001-6E62-45F1-8939-F51B8F259037Q40013790-95F5CFF6-0C8D-4CD1-BB8C-82E1A5CD0343Q42084111-3E01BD2F-8222-4961-9DE0-383C41FA381CQ47425100-57AA3BFB-FCF4-4ABF-A589-E60062F230DAQ48730267-22414540-E121-4BD3-A6A3-A6FED43A96DCQ54378689-E2708FFC-A39C-4201-B98E-0BA2ABF594F0Q56892563-322D9D31-CB37-4349-A568-51E6965EAB15Q57911971-4A17DFBE-97CA-4F95-AF5B-8935A7E97FC7
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Ligand-based vascular targeting of disease.
@ast
Ligand-based vascular targeting of disease.
@en
type
label
Ligand-based vascular targeting of disease.
@ast
Ligand-based vascular targeting of disease.
@en
prefLabel
Ligand-based vascular targeting of disease.
@ast
Ligand-based vascular targeting of disease.
@en
P2860
P356
P1433
P1476
Ligand-based vascular targeting of disease.
@en
P2093
Eveline Trachsel
Jascha-N Rybak
P2860
P356
10.1002/CMDC.200600181
P577
2007-01-01T00:00:00Z